晚期卵巢癌完全细胞减灭术后肿瘤负荷、手术时机与复杂度的预后影响的多因素分析
这项回顾性多中心研究纳入549例IIIC-IV期卵巢癌患者,比较初次减灭术与间歇性减灭术在完全或最小残留病变后的生存获益。初次减灭术组中位无病生存期23.0个月、总生存期84.0个月,均优于间歇性减灭术组。多因素分析显示高腹膜癌指数评分和新辅助化疗与无病生存期及总生存期负相关。
要点
- 初次减灭术组中位总生存期84.0个月,优于3-4周期后间歇性减灭术的50.7个月和6周期后的47.5个月。
- 初次减灭术组中位无病生存期23.0个月,优于3-4周期后间歇性减灭术的18.0个月和6周期后的17.1个月。
- 高腹膜癌指数评分和新辅助化疗与无病生存期及总生存期负相关。
核心结论
- 在术后无或最小残留病变的患者中,初次减灭术较间歇性减灭术提供近三年的生存获益。
- 初次减灭术应继续作为晚期卵巢癌的标准治疗。
研究设计与样本
- 回顾性多中心研究,纳入2008年1月至2015年12月四家高手术量机构收治的IIIC-IV期FIGO卵巢癌患者。
- 共549例患者接受初次减灭术或间歇性减灭术,达到CC-0或CC-1。
- 患者分为三组:初次减灭术组175例(31.9%)、3-4周期新辅助化疗后间歇性减灭术组224例(40.8%)、6周期后间歇性减灭术组150例(27.3%)。
主要发现
- 初次减灭术组、3-4周期后间歇性减灭术组和6周期后间歇性减灭术组的中位无病生存期分别为23.0个月(95%CI=[20.0-29.3])、18.0个月(95%CI=[15.9-20.0])和17.1个月(95%CI=[15.0-20.9]),p<.001。
- 三组中位总生存期分别为84.0个月(95%CI=[68.3-111.0])、50.7个月(95%CI=[44.6-59.5])和47.5个月(95%CI=[39.3-52.9]),p<.001。
- 多因素分析中,高腹膜癌指数评分和新辅助化疗与无病生存期及总生存期负相关。
- 手术复杂度和CC-1与无病生存期负相关。
临床怎么用
- 作者结论认为初次减灭术应继续作为晚期卵巢癌的标准治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the survival benefit of primary debulking surgery (PDS) compared to interval debulking surgery (IDS) after complete cytoreduction (CC-0) or cytoreduction to minimal residual disease (CC-1) in advanced ovarian cancer. Secondary objective was to evaluate the effect of tumor load and surgical complexity on patients' survival. METHODS: A retrospective multicentric study was designed, including patients with IIIC-IV FIGO stage ovarian cancer who underwent PDS or IDS with CC-0 or CC-1 from January 2008 to December 2015 in four high-volume institutions. Patients were classified in three groups: PDS, IDS after 3-4 cycles of neoadjuvant chemotherapy (NACT), and IDS after 6 cycles. Disease-free survival (DFS) and overall survival (OS) were estimated. Univariable and multivariable analyses were conducted. RESULTS: We included 549 patients, 175 (31.9%) underwent PDS, 224 (40.8%) had IDS after 3-4 cycles of NACT, and 150 (27.3%) underwent IDS after 6 cycles. Median DFS in PDS, IDS at 3-4 cycles and IDS at 6 cycles were 23.0 months (95%CI = [20.0-29.3]), 18.0 months (95%CI = [15.9-20.0]) and 17.1 months (95%CI = [15.0-20.9]), respectively; p < .001. Median OS were 84.0 months (95%CI = [68.3-111.0]), 50.7 months (95%CI = [44.6-59.5]) and 47.5 months (95%CI = [39.3-52.9]), respectively; p < .001. In multivariable analysis, high peritoneal cancer index score and NACT were negatively associated to DFS and OS. Surgical complexity and CC-1 were negatively associated to DFS. CONCLUSION: PDS offered a survival gain of almost three years compared to IDS in patients with minimal or no residual disease after surgery. PDS should remain the standard of care for advanced ovarian cancer.
引用
- Angeles MA, Rychlik A, Cabarrou B, et al. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer. Gynecol Oncol. 2020. PMID: 32709536. doi:10.1016/j.ygyno.2020.06.495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。